Sugi Predict

Sugi Predict / Compounds / SCHEMBL7189867

SCHEMBL7189867

SCHEMBL7189867

O=C(Pc1ccccc1)c1c(C(F)(F)F)cccc1C(F)(F)F.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC4 P56524 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TAS2R14 Q9NYV8 2/20 0.37
▸ RXRA P19793 1/20 0.37
▸ RXRB P28702 1/20 0.37
▸ RXRG P48443 1/20 0.37
▸ TXNRD1 Q16881 1/20 0.36
▸ KCNK3 O14649 1/20 0.36
▸ KCNK9 Q9NPC2 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174602 0.91 FABP4 (0.39) HDAC4GAALMNAPOLBRXRA
SCHEMBL7188798 0.87 MAPK14 (0.40) FFAR1MEN1KMT2AMAOB
SCHEMBL7184683 0.85 MEN1 (0.39) HDAC4LMNAALDH1A1TAS2R14KCNK3
SCHEMBL27484269 0.83 LMNA (0.50) GAALMNAALDH1A1TAS2R14KCNK3
SCHEMBL7180687 0.82 MAOB (0.45) GAALMNAALDH1A1MEN1KMT2A
SCHEMBL7182230 0.81 RXRA (0.47) LMNAFFAR1RXRARXRBRXRG
SCHEMBL7187567 0.79 MAPK8 (0.35) GAALMNAPOLBKDM4EMEN1
SCHEMBL7175221 0.79 SLC13A5 (0.39) GAALMNAPOLBALDH1A1HPGD
SCHEMBL7181619 0.78 POLB (0.39) GAALMNAPOLBALDH1A1RXRA
SCHEMBL7188429 0.78 KMT2A (0.49) LMNANFKB1HPGDKCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 HDAC4 2673/4885GAA 4753/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 HDAC4 2526/4885GAA 4793/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.